Stay Up to Date
Breaking News,
Updates, & More
Click Here to

CTC-Driven Treatment Choice May Improve Long-Term Outcomes in Patients with Metastatic Breast Cancer

TOP - January 2023 Vol 16, No 1 - SABCS

Using circulating tumor cell (CTC) count to guide the choice of first-line treatment—chemotherapy or endocrine therapy—improved overall survival (OS) compared with investigator’s choice of treatment for patients with metastatic, estrogen receptor (ER)-positive, HER2-negative breast cancer, according to results from the STIC CTC trial, which were discussed at the 2022 San Antonio Breast Cancer Symposium (SABCS) by François-Clément Bidard, MD, PhD, Co-Coordinator, Breast Cancer Research, Institut Curie, Paris, France, and Professor, Medicine, Department of Medical Oncology, Institut Curie and Université de Versailles Saint-Quentin-en-Yvelines, France.

Among a subgroup of patients representing 25% of the study population, for whom endocrine therapy was the recommended treatment by investigator’s choice but who displayed high CTC count, those who were treated with chemotherapy had an absolute gain of 16 months in median OS and experienced a 47% reduction in risk for death compared with patients in the same group who received endocrine therapy. In this clinically low risk/CTC high group, median OS was 51.8 months in patients treated with chemotherapy compared with 35.4 months in those treated with endocrine therapy (P = .001).

In patients who were deemed clinically high risk but had a low CTC count, who represented 14% of the study population, no significant difference was observed in progression-free survival (PFS) or OS whether patients received chemotherapy or endocrine therapy. In this group, median PFS was 9.3 months in the CTC count–based arm, for whom endocrine therapy is recommended according to guidelines, versus 14.6 months in the standard arm, for whom chemotherapy was selected (P = .54). Median OS was 49.4 months versus 45.9 months (P = .64), respectively.

Study Details

In the STIC CTC trial, 755 patients were randomly assigned in a 1:1 ratio to having their treatment decided by the investigator or by their CTC count. The primary results of this study, which were reported at SABCS in 2018, showed a PFS benefit in patients whose treatment was escalated from endocrine therapy to chemotherapy based on their CTC count.

Guidelines recommend prioritizing endocrine therapy before switching to chemotherapy in patients with metastatic breast cancer, a recommendation based on the favorable side-effect profile of endocrine therapy. Guidelines, however, provide an option to use chemotherapy in patients with aggressive disease, “which has led to highly heterogeneous treatment decisions,” noted Dr Bidard.

“STIC CTC is the first trial to demonstrate the clinical utility of CTC count in metastatic breast cancer,” he said. “The CTC count confirmed the allocated therapy in about 60% of patients and changed the allocated therapy in approximately 40% of ER-positive, HER2-negative patients.”

The study was designed before CDK4/6 inhibitors became the standard of care, admitted Dr Bidard, thus limiting the clinical utility of the findings. In agreement with this point was discussant Daniel F. Hayes, MD, FASCO, FACP, Stuart B. Padnos Professor of Breast Cancer Research, and Professor, Internal Medicine, University of Michigan Rogel Cancer Center, Ann Arbor.

“It’s not clear to me that this is sufficient for clinical utility in context of what we know today,” he said, citing the availability of modern treatments that did not exist when the study was designed. “There was no ancillary treatment with endocrine therapy, CDK 4/6 inhibitors everolimus [Afinitor], alpelisib [Piqray], oral SERDS [selective estrogen receptor degraders], or AKT inhibitors,” he added.

The study was important in that it confirmed that patients with a clinically high risk/low CTC profile could avoid chemotherapy, although this was only a small percentage of patients enrolled, Dr Hayes noted. “It’s inefficient because the CTCs didn’t really help the way you would treat patients,” he said.

To date, payers have not reimbursed for the use of CTC measurement, questioning its clinical utility. “I don’t think the world of CTCs is dead,” Dr Hayes said. “I think they’re part of liquid biopsies. We should continue them as a complement to [circulating tumor] DNA.”

Related Items
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
William King
TOP - May 2023 Vol 16, No 3 published on May 5, 2023 in NCCN 2023 Conference Highlights, Lymphoma, Leukemia
Optimal Systemic Therapy for Renal Cell Carcinoma Is Still Evolving
William King
TOP - May 2023 Vol 16, No 3 published on May 5, 2023 in NCCN 2023 Conference Highlights, Renal-Cell Carcinoma, Kidney Cancer, Urothelial Cancer
Molecular Characteristics Increasingly Define Adult Gliomas
William King
TOP - July 2023 Vol 16, No 4 – Online Only published on May 5, 2023 in Brain Cancer, NCCN 2023 Conference Highlights
Addressing Health Equity in Bladder Cancer Care
William King
TOP - May 2023 Vol 16, No 3 published on May 1, 2023 in Healthcare Equity, Bladder Cancer, Urothelial Carcinoma
What Will It Take to End Cancer As We Know It?
William King
TOP - March 2023 Vol 16, No 2 published on March 14, 2023 in ASCO GU 2023 Highlights
Pausing Endocrine Therapy to Become Pregnant Appears Safe for Women with Breast Cancer
Patricia Stewart
TOP - March 2023 Vol 16, No 2 published on March 14, 2023 in Breast Cancer, SABCS
First-Line Ribociclib plus Endocrine Therapy Beats Chemotherapy for Advanced Breast Cancer
William King
TOP - January 2023 Vol 16, No 1 published on January 10, 2023 in SABCS
AVBCC Panel Discusses Current and Future State of Value-Based Agreements
William King
TOP - January 2023 Vol 16, No 1 published on January 10, 2023 in Value-Based Care, AVBCC Summit Highlights
Capivasertib plus Fulvestrant Yields PFS Improvement in Patients with HR-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
William King
TOP - January 2023 Vol 16, No 1 published on January 10, 2023 in SABCS
Adding Pembrolizumab to Chemotherapy Extends Survival in Women with Cervical Cancer Across Several Key Subgroups
William King
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in Cervical Cancer
Last modified: February 1, 2023